Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurologix, a biotechnology company engaged in gene therapy, has initiated a Phase II study with the GAD-gene within Parkinson's disease. The right to use the GAD-gene has been licensed from Diamyd.
Subscribe to our email newsletter
Neurologix and Diamyd have signed the license agreement in August 2006. It is a running agreement with milestone payments and royalty on sales.
Elisabeth Lindner, president and CEO at Diamyd, said: “These are very positive news for Diamyd, and the fact that GAD can be used within additional therapeutic areas, not only within diabetes, predicts an exciting future for us. That GAD is also used for neurological disorders opens up for further new licensing possibilities.”